All News
New Insights into Uveitis in Spondyloarthritis
Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.
Read Article
ACR21 Best Abstracts We Saw - Day 3 (Monday)
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Read Article
Day 2 Report from ACR21
This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.
Read Article
Axial spondyloarthritis with psoriasis or psoriatic spondylitis
PsA commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research question is whether PsSpA and Axial Spondyloarthritis (AxSpA) with psoriasis are separate conditions or not.
Read Article
My video comment on the cannabidiol (CBD) double-blinded RCT in hand OA/inactive PsA #ACR21 for @RheumNow
Great work by @Joner_MD et al
& kudos to funders @PsoriasisDK @Gigtforeningen @AalborgUH @aalborguni giving us data to answer a question often asked
https://t.co/e0mO0SriUu https://t.co/9DveN4jLls
Links:
David Liew drdavidliew ( View Tweet)
Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6
@RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA
Dr. Antoni Chan synovialjoints ( View Tweet)
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis
👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA
👉🏼No new safety risks with long-term use
👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX
Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Mrinalini Dey DrMiniDey ( View Tweet)
Echos in PsA, RA:
🔹Diastolic dysfxn: 52% of PsA and RA (!), controls 5%
🔹Mitral regurge PsA 84%, Ra 53%, controls 10%
🔹Mild pulmonary valve regurge higher in PsA
(Diastolic dysfxn has been seen in prior RA studies)
https://t.co/QCKR5itfYj
#ACR21 Abst1308 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Supporting date for Ixekizumab in PsA with symptoms of axial involvement.
🔹Improvement in QoL (SF-36), ASDAS, BASDAI50
🔹Maintained at 52 weeks
🔹Stricter criteria (younger, ⬆️CRP) showed similar results
https://t.co/QSJLQTxLcW
#ACR21 Abst#3147
@RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX:
💠IFX-naive: improved disease activity
💠IFX-switched: maintained stable disease
💠No new safety concerns
https://t.co/VGBicnq15w
#ACR21 Abst#0817 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr. Eric Ruderman gives his perspective on PsA data presented during the plenary session on Saturday at the #ACR21 annual meeting.
https://t.co/r9FgBO6VT7 https://t.co/JbV519XQoG
Links:
Dr. John Cush RheumNow ( View Tweet)
This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24.
Reassuring data.
@RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
sheila RHEUMarampa ( View Tweet)
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Links:
Dr. John Cush RheumNow ( View Tweet)
Interesting results where cannabidiol NEG results in RCT in hand OA and PsA. ? Throw out the ‘pot’with the dish water? Did it stimulate appetites? Was pain the same but interference less? Abst#1456 #ACR21 @RheumNow https://t.co/rnz82Paxkr
Janet Pope Janetbirdope ( View Tweet)
CBD for pain in hand OA/inactive PsA:
- works in animal models (many things do)
- other neg RCTs didn't use CBD itself
- DBRCT: 12w continuous, n=136, min dropout
Result:
does absolutely nothing
I bet big money it will be tried again & again
@Joner_MD #ACR21 ABST1456 @RheumNow https://t.co/lZLVrgrKST
David Liew drdavidliew ( View Tweet)
Among 6 CV risk algorithms, the best to predict the carotid plaque (CP) in PsA is the ACC/AHA risk score showed an AUC 0.681 (0.551-0.812), p=0.008, a cut-off point ≥4.8, sensitivity of 63.6%, and specificity of 64.4%
⭐️Prevalence CP 42.3%
Abst #1315 #ACR21 @RheumNow https://t.co/hRvyjetYq3
swethaann23 swethaann23 ( View Tweet)
Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia
⭐️Anemia resolution associated with improved clinical status
#ACR21
#ACRBest
Abs#1331
@RheumNow
https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed
Robert B Chao, MD doctorRBC ( View Tweet)
Knowledge Bowl at #ACR21
⭐️This HLA allele confers a risk for a severe psoriasis phenotype, typically guttate type.
➡️HLA Cw6
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abst1344 #ACR21 @RheumNow observational study of pts w/PsA treated w/b&tsDMARD:pts who achieve MDA (22.8% of pts at 6 mo) more likely to maintain the initiated bDMARD or tsDMARD Rx & less likely to switch from the initiated bDMARD/tsDMARD https://t.co/egFDHV3eQs
Olga Petryna DrPetryna ( View Tweet)
